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Edinburgh EH16 4SB, UK 
 
Abstract 
 
Over 130 brain diseases are caused by mutations that disrupt genes encoding the 
proteome of excitatory synapses. These include neurological and psychiatric 
disorders with early and late onset such as autism, schizophrenia and depression 
and many other rarer conditions. The proteome of synapses is highly complex with 
over 1000 conserved proteins which are differentially expressed in individual 
synapses generating a vast, potentially unlimited, number of synapse types. The 
diversity of synapses and their location in the brain is described by the synaptome. A 
recent study has mapped the synaptome across the mouse brain revealing that 
synapse diversity is distributed into an anatomical architecture observed at scales 
from individual dendrites to the whole systems level. The synaptome architecture is 
built from the hierarchical expression and assembly of proteins into complexes and 
supercomplexes which are distributed into different synapses. Mutations in synapse 
proteins change the synaptome architecture leading to behavioural phenotypes. 
Mutations in the mechanisms regulating the hierarchical assembly of the synaptome, 
including transcription and proteostasis, could also change synapse diversity and 
synaptome architecture. The logic of synaptome hierarchical assembly provides a 
mechanistic framework that explains how diverse genetic disorders can converge on 
synapses in different brain circuits to produce behavioural phenotypes.  
 
Synapse proteome complexity and genetic disorders 
 
The brain is the most anatomically complex organ and synapses are the hallmark of 
this complexity – they are present in vast numbers and their proteome comprises 
thousands of proteins. The discovery in 2000 that the synapse proteome is highly 
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complex(1, 2) transformed concepts of synapse molecular function and has had a 
major impact on uncovering the role of synapses in disease. The complexity of the 
synapse proteome became apparent when proteomic mass spectrometry was used 
to characterise NMDA receptors and MAGUK proteins purified from the mouse brain. 
This revealed that 77 proteins assembled into large multiprotein complexes and this 
increased the number of known proteins ten-fold(1, 2). This discovery raised the 
possibility that there might be many more proteins in the postsynaptic proteome, 
which was confirmed by numerous studies(3-10). It is now widely accepted that there 
is over 1000 highly conserved proteins in the postsynaptic proteome of vertebrate 
excitatory synapses and several thousand proteins in the total synapse proteome. 
 
The first clue that the synapse proteome could be the target of many genetic 
disorders came from the finding that mutations in three of the 77 proteins caused 
intellectual disability and that mutations in 15 of the 77 genes caused learning 
impairments in mice(1). Since then, the combination of synapse proteomic and 
human genetic studies has progressively added to the list of synapse proteins 
involved with human genetic diseases. There have also been many more studies 
demonstrating that mice carrying mutations in synaptic proteins show behavioural 
abnormalities. Characterisation of the postsynaptic proteome purified from human 
brain tissue in 2011 revealed that over 130 brain diseases arise from mutations in 
hundreds of genes encoding proteins in the postsynaptic proteome of excitatory 
synapses(5). These diseases include common and rare neurological, psychiatric, 
neurodevelopmental and neurodegenerative disorders of monogenic and polygenic 
origin. As human genome sequencing is applied to more brain disorders, the number 
of genetic variants targeting synapse proteins continues to increase and this set of 
proteins appears to be responsible for more brain diseases than any other set of 
brain proteins.  
 
Synapses are highly complex and sophisticated signalling machines 
 
The recognition that the synapse proteome is highly complex has required a shift in 
the basic concepts of synapse physiological function. Before 2000, 
neurophysiologists had focussed on the concept that the major role of the synapse is 
to maintain stable synaptic transmission between nerve cells and that changing the 
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stable strength is the primary behavioural function of synapses. With this concept in 
mind, investigations of molecular mechanisms sought to identify synaptic proteins 
that would subserve these roles. John Lisman proposed that a mere handful of 
proteins (the subunits of three protein complexes: the NMDA and AMPA receptors 
and the serine-threonine kinase CamKII) in mammalian excitatory synapses would 
be necessary and sufficient for synaptic transmission and the plasticity underlying 
learning(11). However, proteomics revealed that these proteins represent fewer than 
1% of all proteins in the postsynaptic proteome. Furthermore, genetic studies of 
many of the other 99% of postsynaptic proteins showed that these proteins control 
synapse stable strength too, as well as the dynamic synapse strength and many 
different innate and learned behaviours(12, 13). Moreover, the model that stable 
synapse strength is the core mechanism of learning has been challenged by many 
genetic and pharmacological dissociations between synaptic physiology and learning 
behaviour. Thus, the emerging view is that innate and learned behaviours are 
controlled by diverse sets of proteins in the synapse that act in highly integrated and 
complex molecular networks(14-16). The output of this protein network is the 
modulation of a plethora of cellular mechanisms ranging from instantaneous control 
of synaptic strength to regulation of metabolic, proteostatic and transcriptomic 
cellular mechanisms.  
 
Understanding how the signalling functions of synaptic proteins are integrated 
requires an understanding of the physical structure and organization of the proteins. 
Eukaryotic proteins are rarely found as monomers and almost all are assembled with 
binding partners into multiprotein complexes(17, 18). A survey of over 60 synaptic 
proteins found that all were assembled into a hierarchy of multiprotein complexes 
and supercomplexes (complexes of complexes)(19). The close physical location of 
proteins and their domains within these supramolecular assemblies confers their 
integrative functions and sophisticated signalling properties. Disruption of these 
signalling complexes, as evidenced by mutations in the scaffold protein PSD95 and 
its interacting proteins, causes behavioural abnormalities and interferes with the 
ability of synapses to respond to patterns of nerve cell activity(12, 13, 20, 21). This 
integrative function of multiprotein complexes can explain why mutations in the 
cognate genes converge to produce similar phenotypes. For example, 'studies in 
mice and humans have provided abundant evidence that PSD95 supercomplexes 
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(also known as MASC) are targets of many human disease genes that cause 
cognitive impairments including schizophrenia(15, 22-26).  
 
From synapse proteome complexity to synapse diversity and the synaptome 
 
It has long been known from physiological, pharmacological and anatomical studies 
that there are different synapse types. For example, in the mammalian central 
nervous system the major synapse types can be functionally catalogued into 
excitatory and inhibitory synapses which use the neurotransmitters glutamate and 
GABA, respectively. However, with the advent of gene cloning and molecular 
labelling methods it became apparent that this classification was overly simplistic 
and could not describe the diversity of synapses. There are many subtypes of 
glutamate and GABA receptor subunits and combinations of these are differentially 
expressed in different synapses and confer different physiological properties. When 
we consider that synapses are built from more than 1000 proteins in many different 
structural classes and they too are expressed in different combinations then there is 
a potentially vast, if not unlimited, number of synapse types. Not only can 
combinatorial usage of proteins generate synapse diversity, but so can differential 
splicing and post-translational modifications(14, 27). For example, alternatively 
spliced neurexin isoforms can potentially produce many thousands of different 
proteins from a single gene, and triggering of neurotransmitter receptors can induce 
post-translational changes in hundreds of proteins(14, 27). 
 
Synapse diversity is now beginning to be studied with modern molecular 
techniques(28, 29) but remains poorly understood for at least two reasons. First, 
there is a need to develop a conceptual framework and nomenclature to describe the 
diversity(28, 30). Second, tools are needed to characterise the diversity at the scale 
of the whole brain and not just in small samples(31). As a step toward addressing 
the first issue, the term ‘synaptome’ was coined to describe the full set of synapses 
in the brain(31, 32). Much as the genome describes the location and features of 
each gene, the synaptome describes the location and features of each synapse. Just 
as there has been a set of terms to describe gene structure and genome 
architecture, there is a need to develop a language to describe the synaptome. 
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The first whole brain scale synaptome was recently reported(31). The protein 
composition and morphological features of ~1 billion individual synapses across all 
regions of the mouse brain were used to create unbiased synapse catalogues 
describing synapse diversity and synaptome maps showing the location of all the 
different synapse types (Figure 1). Using high speed spinning disc confocal 
microscopy, the amounts of two proteins (PSD95 and SAP102) found in the 
postsynaptic terminal of excitatory synapses, together with synapse size and shape 
parameters, were quantified. These two proteins, which were genetically labelled in 
mice by fusing fluorescent proteins to the carboxyl-terminus of the endogenous 
protein, are required for the assembly of two distinct multiprotein complexes and thus 
the imaging reveals how supramolecular complexes are the building blocks for 
synapse diversity and synaptome architecture (Figure 1). 
 
To characterise synapse diversity from the brain-wide dataset, a classification 
scheme that defines synapse types based on the molecular composition of the 
synapse as the primary feature and the morphology of synapses as a secondary 
feature was devised(31). Type 1 synapses express PSD95, type 2 express SAP102 
and type 3 express both proteins (Figure 1A-C). The addition of morphological 
parameters enabled each of these types to be further divided into a total of 37 
subtypes. Strikingly, each type and subtype showed a unique anatomical distribution 
pattern across the brain. Each region of the brain could be characterised by a 
particular composition of synapse types and subtypes. Regions of the neocortex and 
hippocampus showed highest synapse diversity, whereas basal structures, such as 
the brainstem, showed lowest diversity (Figure 1D). To facilitate access to the data 
and visualization of synapses across the brain, a set of maps was compiled into the 
Mouse Synaptome Atlas resource (http://synaptome.genes2cognition.org) and a 
versatile viewer called the Synaptome Explorer was developed(31). 
 
The spatial distribution of synapse types and subtypes was shown to be relevant to 
the connectivity of circuits and behavioural functions. For example, different long-
range inputs to the thalamus employed synapses with different combinations of 
proteins. At the global systems level of the brain the synapse composition of different 
brain regions exhibited a network topology that correlated with the topology of the 
functional connectivity of those regions as measured with resting state functional 
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magnetic resonance imaging (fMRI). This indicates that the synaptome molecular 
architecture is relevant to the large-scale electrophysiological network properties of 
the brain.   
 
The study of synapse diversity arising from only two postsynaptic proteins revealed 
combinatorial principles that extend to any number of other synapse proteins. Each 
protein had a unique synaptome map. In other words, each protein was localized into 
a unique subset of the total number of synapses. As a result, protein combinations 
generate synapses containing either or both proteins. The number of synapse types 
arising from n different proteins is described as Ntypes = 2n-1, and 50 proteins (< 5% of 
the synapse proteome) could potentially generate more types than there are 
synapses in the human brain (5 x 1014). With the addition of size and shape 
parameters, the number of synapse subtypes expands exponentially to a number far 
beyond the largest and most complex brain of any animal. While there is no doubt 
that there is vast synapse diversity conferred by molecular combinatorial 
mechanisms, there are in fact constraints that limit the combinations and diversity. 
As described above, the proteome of individual synapses is not a soup of 
promiscuously expressed individual proteins but is a structured assembly of protein 
complexes and supercomplexes that are built from combinations of proteins, and 
these supramolecular structures have constraints that limit and define their protein 
composition (Figure 2). Considering that synapses are composed of combinations of 
complexes (and supercomplexes) and these in turn are composed of combinations 
of proteins, then the impact of a given mutation on a subset of synapses will be 
determined by the rules of assembly of this molecular hierarchy (Figure 2).  
 
Synaptome modification in genetic disorders  
 
Synapse diversity and synaptome architecture have important implications for 
understanding the mechanism of genetic disorders and where they exert their effects 
in the brain. In the following section, I will present evidence that suggests that most, 
and perhaps all, brain diseases will manifest with changes in synaptome architecture 
and that different diseases will target specific subsets of synapse types. Mutations 
can act through at least four different mechanisms to change the synaptome: 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz178/5538900 by guest on 30 July 2019
 7 
Mechanism 1: mutations target subsets of vulnerable synapses 
As exemplified by the three synapse types that arise from the combinatorial 
expression of two synapse proteins, a mutation that results in a change in one 
protein will affect a subset of synapses (Figure 3A, B). Thus, to understand which 
synapses (and circuits) are affected by a disease gene it will be necessary to create 
a synaptome map of its cognate protein. The subset of synapses within this 
synaptome map can be considered to be the genetically “vulnerable” synapses and 
those that are unaffected as the “resilient” synapses. The versatile synaptome 
mapping pipeline SYNMAP is well suited and scalable for creating these maps(31). 
 
Mechanism 2: mutations induce synaptome reprogramming 
Synaptome reprogramming is a fascinating and potentially important regulatory 
mechanism in disease(31). We found that mutations in PSD93 and SAP102 (Psd93 
knockout mice, which are a model of schizophrenia, and Sap102 knockouts, which 
are a model of X-linked intellectual disability) changed the synaptome map of PSD95 
(Figure 3C). Thus, a mutation in one synapse protein changes the synaptome map 
of another synapse protein. To understand the mechanisms involved we reasoned 
that because PSD93 is a component of PSD95 supercomplexes then the mutation 
could change the supercomplex localisation and the PSD95 synaptome map. This 
suggests that mutations in other PSD95-interacting proteins could also change the 
PSD95 synaptome.  However, this mechanism would not apply to SAP102 because 
it is in physically distinct complexes to those housing PSD95. This suggests that a 
mutation in a different complex could also change the PSD95 synaptome. Together, 
these observations suggest that a mutation in any synapse protein could change the 
synaptome map of PSD95 through synaptome reprogramming. Thus, when we 
consider how a mutation in a gene could generate a synaptome phenotype we need 
to consider the role of mechanisms 1 and 2. At a practical level, it means that in 
addition to mapping the synaptome of the mutant protein, it will be important to map 
the synaptome of other synapse proteins. In this model, we are considering that the 
connectome anatomy has not changed and it is the synapse proteins that are 
different. To fully dissect the consequences of the mutation on the connectome and 
the synaptome, in future studies it will be useful to use conditional knockout 
approaches and measurements of dendritic and axonal anatomy. 
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Mechanism 3: lifespan temporal synaptome architecture and phenotype penetrance 
One of the most puzzling features of some germline mutations is that their 
phenotypes manifest at late ages and in particular regions of the brain despite the 
gene being widely and continuously expressed(33). A parsimonious explanation for 
this phenomenon is that the ‘molecular context’ of the mutation changes with age 
and brain region and, as a result, the penetrance of the mutation is affected. In the 
context of synaptic disorders, a change in synapse diversity with age and brain 
region might account for a genetic disorder targeting a particular brain circuit at a 
particular age. Toward this possibility, we have been mapping the synaptome of the 
mouse brain across the lifespan and find that there are marked changes at different 
ages (M. Cizeron, Z. Qiu, E. Fransén, S.G.N. Grant, personal communication). It is 
very likely that the two mechanisms described above will vary with age and brain 
region and studying this in the context of genetic disorders may show why some 
genetic diseases exert their phenotypes later in life. 
 
Mechanism 4: disruption to the molecular hierarchy that assembles the synaptome 
The synaptome is built from a hierarchy of molecular mechanisms ranging from the 
transcriptome (e.g. the cell type-specific transcriptome), protein turnover (e.g. 
translation, proteostasis), mechanisms of assembly of complexes into 
supercomplexes and trafficking of these assemblies into different synapses (Figure 
2)(31, 34, 35). Above, we considered the impact of genetic disorders that directly 
target the synapse proteome and the assembly of complexes and supercomplexes 
into the synaptome. However, in the broader context of this hierarchical assembly 
model there will be mutations that interfere with mechanisms at all levels and these 
will be expected to impact on synapse diversity and synaptome architecture. 
Although there is much research to be conducted toward understanding how basic 
cell biological mechanisms control the synaptome architecture of the whole brain, 
focussed studies have shown that mice carrying a mutation in Fmr1, an RNA-binding 
protein involved with autism, exhibit changes in distinct subpopulations of synapses 
in the neocortex(36). It is likely that synaptome pathology will be a common feature 
of autism as many of the susceptibility genes encode synapse proteins and 
regulators of proteostasis(37). Convergence of phenotypes arising from mutations in 
different classes of disease genes may also occur in schizophrenia because the 
susceptibility genes are enriched in proteins in PSD95 supercomplexes(22-26).  
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Given the synapse proteome complexity and its diversity of protein types, it is very 
likely that mutations in most general regulatory mechanisms (transcription, 
translation and protein turnover) will impact on the synaptome. Human brain 
diseases arise from a wide range of different genomic structural alterations including 
mutations affecting gene regulation, protein structure, copy number and 
chromosomal rearrangements. All of these genomic structural changes could impact 
on the molecular hierarchy and thereby change synaptome architecture. Thus, 
synaptome mapping in models of these genetic and cell biological mechanisms will 
be rich areas of investigation in the future. 
 
The functional importance of synaptome architecture for behaviour 
 
I have described how synapse diversity and synaptome architecture will be targeted 
in a very wide range of diseases, and from this it should be clear that we need to 
understand how the synaptome is important for behaviour so that we can interpret 
how these diseases produce their behavioural phenotypes. Central to this issue is 
the need to understand the functional importance of synapse diversity in behaviour, 
which is a subject that has received very little attention and is not part of the 
standard literature on synapse physiology and behaviour. It is well known that 
synapse proteome composition controls synaptic transmission and synaptic plasticity 
and thus, by extension, different synapse types will show different functional 
properties. We have developed ‘Synaptomic Theory’ to explain how synapse 
diversity and synaptome maps can store information (innate and learned behaviours) 
that can be “recalled” by patterns of nerve cell activity(38).  
 
Because the release of a neurotransmitter generates a postsynaptic response 
amplitude that is modulated during the train of activity, synapses with different 
proteomes show different patterns of response. This means that the proteome of a 
synapse type can be identified by its response to a pattern of activity. In other words, 
the information stored in the proteome of individual synapses can be functionally 
accessed or recalled by examining the response of that synapse to a pattern of 
activity. The spatial distribution of these different synapse types on dendrites, cell 
types and brain regions will therefore control the physiological output from their 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz178/5538900 by guest on 30 July 2019
 10 
relevant circuits. Altered synaptome maps arising from genetic disorders could then 
produce different electrophysiological outputs that could produce behavioural 
phenotypes associated with the disease. 
 
Concluding comments and future perspectives 
 
One of the most powerful features of synapse proteome and synaptome biology is 
their direct connection to the genome and hence genetic disorders. A huge number 
of diseases directly target the genes encoding the synapse proteome, and each 
could potentially result in an altered synaptome architecture. A further set of 
diseases targeting regulatory proteins could also result in changes to the synaptome. 
It seems probable that genetic disorders that interfere with non-neuronal cells may in 
some cases alter the synaptome too, since astrocytes and microglia are known to 
modulate synapse biology. Because synapse proteomes are spatially distributed into 
diverse synapses and they are distributed into an architecture, the synaptome and its 
hierarchical molecular assembly provides a roadmap from the gene to the brain 
circuit and to behaviour that can be applied in genetic disorders of the brain.  
 
Synaptomic methods are in their infancy and there is a need to enhance and develop 
many aspects of the technology. Alongside the molecular labelling and imaging 
technology there is a need to expand the Mouse Synaptome Atlas resource with 
data across all ages of the lifespan and in the many different neuronal cell types. 
Linking synapse types and cell types (defined by transcriptomes) will be of major 
importance for linking genes to the anatomy and function of neural circuits. 
 
There are no systematic synapse catalogues that embrace our current knowledge of 
synapse proteome complexity. We require research programs that will identify the 
range of synapse types using protein markers, and new classification schemes of 
synapse types that take into consideration the complexity and dynamics of the 
synapse proteome. This knowledge will be of value in identifying the synapse types 
and subtypes that are the targets of genetic disorders. 
 
Programs of research that map the synaptome will be required in human and in 
organisms that are considered as models for human brain disease. We have begun 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz178/5538900 by guest on 30 July 2019
 11 
to apply the SYNMAP pipeline(31), which was developed for the mouse, to the 
human brain and found that it is possible to map billions of synapses and catalogue 
the synapse types in the synaptome of normal and Alzhiemer’s disease human 
postmortem tissue (O. Curran, C. Smith, Z, Qiu, S.G. Grant, personal 
communication). Very little is known about species differences in synapse diversity 
and this may be very important in understanding the utility of model organisms and 
why drugs target certain synapse types. Studying the conserved and derived 
features of synaptomes in different species will enable us to identify the ancestral 
synaptome maps and the lineage-specific changes that characterise each species. 
 
The synaptome contains three-dimensional molecular information about brain 
structure and function and has the potential to link with the established brain imaging 
methods used in the clinic. We have shown that the differential synapse proteome 
composition of regions of the human neocortex correlates with functional brain 
imaging (PET and fMRI)(39) and that the mouse synaptome network topology 
correlates with the resting state fMRI network(31). These findings are a step toward 
using fMRI and PET imaging to study the synaptome in living individuals over the 
lifespan. 
 
In conclusion, the complexity of the synapse proteome and the remarkable and 
beautiful architecture of the synaptome present a framework that enables us to 
understand the link between genetic disorders, the architecture of the brain and 
behaviour. Synaptomic methods will enable a new range of basic science 
investigations that, together with genetic and clinical imaging approaches, have the 
potential to provide a rational and general model of the genetic basis of behavioural 
disorders.  
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Figure 1 
 
 
 
Figure 1. Synaptome mapping in mouse. 
A. Genes expressing synapse proteins are tagged in mice by fusing a genetically 
encoded fluorescent protein onto the C-terminus of postsynaptic scaffold 
proteins that assemble signalling complexes (PSD95, green; SAP102, 
magenta). These complexes are distributed into different synapse types that 
can be visualized with confocal microscopy. The synaptome map is built by 
quantification of synapse types from regions of the mouse brain. 
B. Coronal mouse brain section showing the differential distribution of PSD95 
(green) and SAP102 (magenta). 
C. Synaptome map of a coronal section showing the dominant or major subtype 
from 37 subtypes in different regions. 
D. Synaptome map showing the extent of synapse diversity in different regions of 
the mouse brain. Figures adapted from (31). 
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Figure 2 
 
 
 
Figure 2. Synaptome hierarchical assembly. The diversity of synapse types and their 
spatial distribution in the synaptome arise from a hierarchical regulatory mechanism 
controlling gene and protein expression, assembly of proteins into complexes and 
supercomplexes, and distribution of these supramolecular assemblies into synapses. 
Mutations acting on regulatory mechanisms at all levels of the hierarchy could 
influence synapse diversity and synaptome architecture. 
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Figure 3 
 
 
 
Figure 3. Mutations reprogram synaptome architecture.  
A. Model of a normal synaptome comprising 36 synapses of three types 
assembled from two proteins (PSD95 and SAP102). Type 1 synapses 
express only PSD95, type 2 express only SAP102, and type 3 a mixture of 
both proteins.  
B. A mutation that knocks out PSD95 changes the synaptome architecture by 
abolishing type 1 synapses (empty circles in top two rows) and converts type 
3 to type 2 synapses. 
C. A mutation that knocks out SAP102 does not affect type 1 synapses, but 
abolishes type 2 synapses and converts type 3 synapses into type 1 
synapses.  
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